Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Stratigos

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
International Journal of Dermatology|July 25, 2024
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areasNatalia Rompoti, Theognosia Vergou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 20, 2024
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasisNatalia Rompoti, Irene Stefanaki, Pantelis Panagakis, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2015
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guidelineAlexander Stratigos, Claus Garbe, Celeste Lebbe, et al.
Dermatology and Therapy|April 10, 2024
Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based StudyMichela Starace, Francesca Pampaloni, Elisabeth Lazaridou, et al.
The Journal of Investigative Dermatology|November 18, 2011
Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutationsMatthieu Lacroix, Laetitia Lacaze-Buzy, Laetitia Furio, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 16, 2026
Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failureIrene Stefanaki, Ioannis-Alexios Koumprentziotis, Charitomeni Vavouli, et al.
Clinical and Experimental Dermatology|November 8, 2025
Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in psoriasis patients: results from a real-world multicentre studyAlexander Katoulis, Evangelia Papadavid, Ioannis-Alexios Koumprentziotis, et al.
Journal of Clinical Medicine|February 24, 2024
Use of Dermoscopy among Greek Dermatologists in Everyday Clinical Practice: A National Questionnaire-Based StudyDimitrios Sgouros, Eleni Routsi, Athina Evangelodimou, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 24, 2025
Pregnancy-associated melanoma epidemiology: A multicentre European studyMaria Kostaki, Michaela Plaka, Vasiliki Chardalia, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2026
Pregnancy-associated melanoma: A distinct entity requiring vigilanceMaria Kostaki, Michaela Plaka, Vasiliki Chardalia, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
International Journal of Dermatology|July 25, 2024
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areasNatalia Rompoti, Theognosia Vergou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 20, 2024
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasisNatalia Rompoti, Irene Stefanaki, Pantelis Panagakis, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2015
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guidelineAlexander Stratigos, Claus Garbe, Celeste Lebbe, et al.
Dermatology and Therapy|April 10, 2024
Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based StudyMichela Starace, Francesca Pampaloni, Elisabeth Lazaridou, et al.
The Journal of Investigative Dermatology|November 18, 2011
Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutationsMatthieu Lacroix, Laetitia Lacaze-Buzy, Laetitia Furio, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 16, 2026
Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failureIrene Stefanaki, Ioannis-Alexios Koumprentziotis, Charitomeni Vavouli, et al.
Clinical and Experimental Dermatology|November 8, 2025
Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in psoriasis patients: results from a real-world multicentre studyAlexander Katoulis, Evangelia Papadavid, Ioannis-Alexios Koumprentziotis, et al.
Journal of Clinical Medicine|February 24, 2024
Use of Dermoscopy among Greek Dermatologists in Everyday Clinical Practice: A National Questionnaire-Based StudyDimitrios Sgouros, Eleni Routsi, Athina Evangelodimou, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 24, 2025
Pregnancy-associated melanoma epidemiology: A multicentre European studyMaria Kostaki, Michaela Plaka, Vasiliki Chardalia, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2026
Pregnancy-associated melanoma: A distinct entity requiring vigilanceMaria Kostaki, Michaela Plaka, Vasiliki Chardalia, et al.
Pageof 16